Literature DB >> 6388363

Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol.

G Serban, S Siegel.   

Abstract

The improvement in the clinical methods of identifying borderline subjects makes it necessary to reevaluate the efficacy of the treatment offered them. A random sample of 52 borderline and schizotypal patients was treated with two major neuroleptics, thiothixene and haloperidol, in a double-blind study. Eighty-four percent were markedly to moderately improved at 3-month follow-up; the patients responded better to thiothixene than to haloperidol. The main areas of positive response were those of cognitive disturbance, derealization, ideas of reference, anxiety, and depression. The patients also showed improvement in self-image and social functioning. There was no significant relationship between diagnosis and outcome of treatment.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6388363     DOI: 10.1176/ajp.141.11.1455

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  10 in total

Review 1.  The spectrum of schizophrenia.

Authors:  M P Weller
Journal:  Postgrad Med J       Date:  1987-12       Impact factor: 2.401

2.  The successful pharmacological treatment of adolescents and young adults with borderline personality disorder: a preliminary open trial of flupenthixol.

Authors:  S Kutcher; G Papatheodorou; S Reiter; D Gardner
Journal:  J Psychiatry Neurosci       Date:  1995-03       Impact factor: 6.186

Review 3.  Pharmacological interventions for borderline personality disorder.

Authors:  Jutta Stoffers; Birgit A Völlm; Gerta Rücker; Antje Timmer; Nick Huband; Klaus Lieb
Journal:  Cochrane Database Syst Rev       Date:  2010-06-16

4.  Neurobehavioral study of borderline personality disorder.

Authors:  R van Reekum; C A Conway; D Gansler; R White; D L Bachman
Journal:  J Psychiatry Neurosci       Date:  1993-05       Impact factor: 6.186

Review 5.  Efficacy and tolerability of pharmacotherapies for borderline personality disorder.

Authors:  Silvio Bellino; Erika Paradiso; Filippo Bogetto
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 6.  Medications in the treatment of borderline personality disorder 2006.

Authors:  Deanna Mercer
Journal:  Curr Psychiatry Rep       Date:  2007-02       Impact factor: 8.081

7.  Psychopharmacologic treatment of borderline personality disorder.

Authors:  Luis H Ripoll
Journal:  Dialogues Clin Neurosci       Date:  2013-06       Impact factor: 5.986

8.  Auditory Verbal Hallucinations in Borderline Personality Disorder and the Efficacy of Antipsychotics: A Systematic Review.

Authors:  Christina W Slotema; Jan Dirk Blom; Marieke B A Niemantsverdriet; Iris E C Sommer
Journal:  Front Psychiatry       Date:  2018-07-31       Impact factor: 4.157

9.  Review of pharmacologic treatment in cluster A personality disorders.

Authors:  Jessa Koch; Taylor Modesitt; Melissa Palmer; Sarah Ward; Bobbie Martin; Robby Wyatt; Christopher Thomas
Journal:  Ment Health Clin       Date:  2016-03-08

Review 10.  Diagnosis and treatment of schizotypal personality disorder: evidence from a systematic review.

Authors:  Sophie K Kirchner; Astrid Roeh; Jana Nolden; Alkomiet Hasan
Journal:  NPJ Schizophr       Date:  2018-10-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.